Protagenic's $5M Placement Shows the Gap Between Windward's IPO and Microcap Funding
Protagenic's $1.5M upfront, up to $5M milestone-linked raise for PT00114 contrasts with Windward's $251.2M IPO and puts a spotlight on staged, warrant-heavy financing.
What happened
Protagenic Therapeutics (PTIX) announced on November 11, 2026 a private placement of up to $5 million. Only $1.5 million is upfront. Up to $3.5 million more depends on the exercise of milestone-linked warrants. The proceeds are earmarked for IND-enabling work and a Phase 1/2a trial of PT00114, a neuropeptide for generalized anxiety disorder (GAD).
The regulatory backdrop is the main support for the raise. The company says FDA's August 2026 pre-IND responses identified no deficiencies precluding an IND. It targets IND submission in late Q1 2027 and first dosing in Q2 2027. The excerpt we reviewed does not give the investors, pricing, warrant terms or the specific milestones that trigger the additional capital, so the full economics are not yet assessable.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- Protagenic announces private placement of up to $5M to move PT00114 into first U.S. GAD trial Protagenic Therapeutics, Inc.\new · 17 Nov 2026
- Air Water Ventures agrees to buy Proud Source Water in deal worth up to $150 million Air Water Ventures Ltd · 17 Nov 2026
- Kyntra Bio halts FG-3246 prostate cancer work, cuts royalty-financing cap and plans roxadustat MDS Phase 3 Kyntra Bio, Inc. · 16 Nov 2026
- NervGen Pharma reports C$80.1M cash at Q3 2026 after May public offering; nine-month net income of C$2.5M Nervgen Pharma Corp. · 16 Nov 2026
- Windward Bio closes $251.2M IPO and private placement, with underwriters' option exercised in full Windward Bio Group AG · 16 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Retension's $51.75M IPO buys a Phase 2b readout, but trial costs will set the clock
Retension's first earnings report since its upsized October IPO shows a $5.9M quarterly loss and a single catalyst: RTN-001 Phase 2b data in H1 2027. Peers show how thin other routes to capital are.
Insight Molecular's $15M raise shows how thin the small-cap diagnostics funding market is
IMDX's $1.75-per-share offering, with pre-funded warrants and a transplantation R&D pitch, sits at the small end of a financing spectrum that runs from a $51.75M IPO to royalty sales.
Kyntra's prostate exit shows how thin the funding runway is for a biotech that has to reset
After a Phase 2 interim miss, Kyntra Bio is cutting its royalty-financing cap and pivoting to roxadustat in MDS, and its plan is subject to funding in a split biotech capital market.